Companies /Healthcare

Precigen Inc

NASDAQ: PGEN Biotechnology
$4.29
▼ $0.01 (−0.23%) today
Markets closed · 10:12pm ET

PGEN at a Glance

Valuation
Market cap
$1.5B
P/E ratio
39.1
Profitability
Revenue (TTM)
$156.9M
Profit margin
15.5%
EPS (TTM)
$0.11
Price
52-week range
$3 – $9
Street target
$13.67

Headquartered in Germantown, MD Fiscal year ends December NASDAQ: PGEN precigen.com

About Precigen

Precigen, Inc. is a commercial-stage biopharmaceutical company developing precision medicines for difficult-to-treat diseases with high unmet need, focused on immuno-oncology, autoimmune disorders and infectious diseases.

Its lead commercial product is PAPZIMEOS (zopapogene imadenovec-drba). This non-replicating adenoviral vector-based immunotherapy targets HPV 6 and HPV 11 proteins. It received full FDA approval in August 2025, without a confirmatory trial requirement, as the first approved therapy for adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is administered subcutaneously and is sold in the US through academic centers, infusion centers and community practices. It has payer coverage across private plans, Medicare and Medicaid, and a permanent J-code. A European Marketing Authorization Application is under EMA review.

PAPZIMEOS is built on Precigen's AdenoVerse immunotherapeutic platform, which received FDA Platform Technology Designation in September 2026. The pipeline also includes PRGN-2009, an AdenoVerse immunotherapy in Phase 2 trials for HPV-associated oropharyngeal cancer and recurrent/metastatic cervical cancer.

Precigen also earns service revenue through its Exemplar subsidiary. Updated

Latest Activity

PGENPrecigen
Q3 2026
EPS
$0.08
est $0.08+$0.00
Revenue
$74M
est $72M+3.6%

Precigen hit positive operating cash flow a quarter ahead of its own target, with PAPZIMEOS net product revenue of $72.96 million. Second straight profitable quarter after a year of losses, and the EMA review plus pediatric development are the next catalysts.

Quarterly EPS — reported vs estimate

PGEN Coverage

10:20am ET
Investing

3 Penny Stocks to Buy With $500

Are you interested in investing in penny stocks? Though doing so does come with risk, making the right investment decisions in the penny stock category can produce eye-opening returns. While the profits…

Joshua Rodriguez

Frequently Asked Questions

What does Precigen do?

Precigen, Inc. is a commercial-stage biopharmaceutical company developing precision medicines for difficult-to-treat diseases with high unmet need, focused on immuno-oncology, autoimmune disorders and infectious diseases. Its lead commercial product is PAPZIMEOS (zopapogene imadenovec-drba).

What is the PGEN stock price target?

The Wall Street consensus 12-month price target for PGEN is $13.67.